The invention relates to methods of selecting a subject and methods of treating the subject with an anti-VLA-l antibody. In one embodiment the first therapeutic agent is a DMARD (Disease Modifying Antirheumatic Drug) such as gold salts; hydroxychloroquine; an antifolate such as methotrexate; a pynmidine synthesis inhibitor such as leflunomide; or a sulfa drug such as sulfasalazine. For example the DMARD can be methotrexate administered at a dose of mg/week or less; leflunomide administered at a dose of 20 mg/day or less; sulfasalazine administered at a dose of 3000 mg/day or less; or hydroxychloroquine administered at a dose of 400 mg/day or less.

暂无附图